Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?
This article was originally published in The Pink Sheet Daily
Executive Summary
Andreas Rummelt will take over as head of the Sandoz generics business effective Nov. 1. His appointment reflects an enhanced focus on manufacturing and development rather than acquisitions, CFO Breu says. Novartis is re-evaluating the structure of Sandoz in light of difficult pricing environments in the U.S. and Germany.